[Recent trends in first-line therapy for H. pylori infection in the world].
Miki
Ikuya
I
Department of Clinical Molecular Medicine, Division of Diabetes, Digestive and Kidney Diseases, Kobe University Graduate School of Medicine.
Shirasaka
Daisuke
D
Morita
Yoshinori
Y
Aoyama
Nobuo
N
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage*; D014943:Global Health; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D010349:Patient Compliance; D054328:Proton Pump Inhibitors
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors